Results from the cobra-reduce trial reported at TCT Connect

October 17, 2020

NEW YORK - October 17 , 2020 - For patients undergoing percutaneous coronary intervention (PCI) that also require oral anticoagulation, treatment with a nanotechnology polymer-coated stent plus 14-day dual anti-platelet therapy (DAPT) did not reduce bleeding or establish non-inferior outcomes for thrombotic events compared with a drug-eluting stent (DES) and standard three or six-month DAPT therapy.

Findings were reported today at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

COBRA-REDUCE was a randomized, open-label, active-controlled, assessor-blinded, multi-center trial. A total of 996 patients were enrolled between February 2016 and May 2020 at 59 sites in Europe and the United States. Patients at high bleeding risk (HBR) due to requirement for oral anticoagulation were randomized at the time of PCI to treatment with the COBRA-PzF stent followed by a very short duration (14 days) of DAPT or an FDA-approved new generation DES followed by guideline-recommended DAPT duration (three or six months).

The primary endpoints were BARC class ? 2 bleeding beyond 14 days or after hospital discharge (whichever is later) at six months post-randomization and composite of death, myocardial infarction (MI), definite/probable stent thrombosis (ST), or ischemic stroke at six months.

Secondary endpoints included composite endpoint of all cause death, MI, definite/probable ST, ischemia-driven TLR, or ischemic stroke; composite of cardiac death and MI; ischemia driven TLR; definite/probable ST; ischemic stroke; BARC class 3-5 bleeding; TIMI major bleeding; TIMI major or minor bleeding; and health economic utilities.

The rate of bleeding in the test group (COBRA-PzF stent with short DAPT) was 7.5 % and in the control group (DES with standard DAPT) was 8.9% (p=0.477). The rate of the composite thrombotic endpoint was 7.7% in the test group and 5.2% in the control group (Difference +2.5% (95% CI 5.15%), pnon-inferiority=0.061).

"In patients undergoing PCI for acute or chronic coronary syndromes who are receiving oral anticoagulation with or without dose reduction, stenting with Cobra PzF stents with 14 days DAPT did not reduce BARC 2-5 bleeding and did not meet non-inferiority criteria with respect to thrombotic events compared with standard DES and 3-6 months of DAPT," said Robert A. Byrne MB, BCh, PhD. Dr. Byrne is Director of Cardiology, Mater Private Hospital, Dublin and Chair of Cardiovascular Research, Royal College of Surgeons in Ireland. "Treatment with the Cobra PzF stent was safe with ST rates considerably lower than those seen in earlier trials with HBR patients despite DAPT duration of only 14 days."

"Ongoing follow-up and planned analysis of secondary outcomes at 12 months is needed to assess comparative efficacy of the treatment arms in relation to the study devices. Analyses of bleeding events according to medication compliance, OAC dose, and number of ARC-HBR criteria will permit examination of interaction between treatment effect, anticoagulation intensity and baseline bleeding risk," Dr. Byrne said.
The COBRA-REDUCE trial was funded by CeloNova Biosciences. Dr. Byrne reported the following disclosures: Research contract with institution of prior employment: CeloNova Biosciences.

About CRF

The Cardiovascular Research Foundation (CRF) is one of the world's leading nonprofit organizations specializing in interventional cardiology innovation, research, and education. CRF is dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For nearly 30 years, CRF has helped pioneer medical advances and educated doctors on the latest treatments for heart disease. CRF is comprised of the CRF Skirball Center for Innovation, CRF Clinical Trials Center, CRF Center for Education, CRF Digital, TCTMD, and Structural Heart: The Journal of the Heart Team.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the premier educational meeting specializing in interventional cardiovascular medicine. Now in its 32nd year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.

For more information, visit and

Cardiovascular Research Foundation

Related Ischemic Stroke Articles from Brightsurf:

Amniotic fluid may yield new, better treatment for ischemic stroke
A study released in STEM CELLS Translational Medicine points the way to a possible new avenue of treatment for ischemic stroke.

Risk of ischemic stroke in patients with COVID-19 compared with influenza
This observational study compares the rate of ischemic stroke among patients with COVID-19 compared with influenza in two New York hospitals.

Research shows COVID-19 is an independent risk factor for acute ischemic stroke
COVID-19 infection is significantly associated with strokes, and patients with COVID-19 should undergo more aggressive monitoring for stroke.

Ischemic stroke rates decrease during COVID-19 pandemic
Research reveals fewer people have been admitted to stroke centers in Michigan and northwest Ohio since the onslaught of the COVID-19 pandemic, and significantly fewer patients received a mechanical thrombectomy for their ischemic stroke.

Antioxidant treatment in acute ischemic stroke may delay the onset of Alzheimer's dementia
There is a considerable overlap between vascular risk factors and risk factors of Alzheimer's disease (AD).

AJR: Smartphone, laptop prove reliable and accurate for acute ischemic stroke decision
A unique assessment of imaging-based recommendations for the administration of IV recombinant tissue plasminogen activator based on unenhanced brain CT scans, the results published ahead-of-print in this April article from the American Journal of Roentgenology (AJR) constitute a strong foundation for the development of mobile-based telestroke services because they increase neuroradiologist availability and the possibility of using reperfusion therapies in resource-limited countries.

Stable ischemic heart disease in the older adult
In the current issue of Cardiovascular Innovations and Applications, Juan R.

Diabetes mellitus and stable ischemic heart disease
In the current issue of Cardiovascular Innovations and Applications, Cody Schwartz and David Winchester from the Malcom Randall VAMC, Gainesville, Fla., USA consider diabetes mellitus and stable ischemic heart disease.

Contemporary management of patients with stable ischemic heart disease
In the current issue of Cardiovascular Innovations and Applications, Radmila Lyubarova, Joshua Schulman-Marcus and William E.

Epidemiology, pathophysiology, and therapeutic targets in stable ischemic heart disease
In the current issue of Cardiovascular Innovations and Applications, C.

Read More: Ischemic Stroke News and Ischemic Stroke Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to